Clinical Trial

A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study will evaluate two study drugs called ubamatamab and marlotamig, to see if they can help treat advanced or metastatic Non-Small Cell Lung Cancer (NSCLC), and sarilumab, to evaluate to see if it can help with immune-related side effects from ubamatamab. The study is looking at: * How well ubamatamab and marlotamig work(s) * The side effects that ubamatamab and marlotamig might cause * How much ubamatamab and marlotamig is in the blood at different times * If the body makes antibodies to ubamatamab and/or marlotamig, this may cause the ubamatamab to not work as well
Protocol Amendment History 3 changes
notable Trial sites expanded: 12 -> 15 locations 2026-08-14
notable Trial sites expanded: 5 -> 10 locations 2026-06-17
notable Trial sites expanded: 1 -> 4 locations 2026-05-08
Trial Details
NCT Number NCT07154290
Lead Sponsor Regeneron Pharmaceuticals
Conditions Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung
Enrollment 300 participants
Start Date 2026-03-18
Primary Completion 2030-06-10 (estimated)
Study Completion 2030-06-10 (estimated)
Updated on ClinicalTrials.gov 2026-08-13